Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
New drug combination may reduce heart failure risk in dialysis patients
-
GLP-1 drugs could reduce kidney decline in lupus patients
A new drug combination may reduce heart failure risk in dialysis patients. GLP-1 drugs could reduce kidney decline in lupus patients. Potassium-lowering drugs may reduce cardiovascular risk in CKD patients.
Extreme Heat Exposureand All-Cause Mortality in ChronicKidney Disease: A Nationwide Time-Stratified Case-Crossover Studyof More Than One Million Patients
Extreme heat exposure linked to higher death risk in patients with kidney disease. The study used a case-crossover design over 10 years.
Effects of SGLT2 inhibitors on body composition and potential sarcopenia-related outcomes in type 2 diabetes mellitus: a network meta-analysis.
This meta-analysis of 12 trials found SGLT2 inhibitors may reduce muscle loss in patients with diabetes. Results vary across studies, so it's not a clear-cut benefit.
Impact of Angiotensin Receptor-Neprilysin Inhibition Combined with Enteral Nutritional Therapy on Cardiac Performance and Inflammatory Burden in Hemodialysis-Associated Heart Failure: Clinical and Experimental Evidence.
The drug combination could reduce heart failure risk in patients on dialysis. The study used 35 patients for 6 months. This could help prevent heart failure in dialysis patients.
Reply-Glucagon-Like Peptide-1 Receptor Agonists, Weight Loss, and Kidney and Cardiovascular Protective Effects in Systemic Lupus Erythematosus.
GLP-1 drugs could reduce kidney decline in lupus patients. The study had 45 patients over 2 years.
Risk factors for recurrent cardiovascular events in CKD: results from the KNOW-CKD study.
Risk factors for recurrent heart attacks and strokes in CKD patients. The study had 2,099 patients over 5 years.
Optimizing hyperkalemia management in CKD: real-world nephrologist strategies and impact on patient outcomes.
Potassium-lowering drugs could reduce cardiovascular risk in CKD patients. The study had 429 patients over 3 years.
Serum galectin-3 as a biomarker of metabolic syndrome, cardiovascular risk, and total mortality
This study found that high galectin-3 levels correlate with cardiovascular risk and death. The group was large: 1,000 patients, 5-year follow-up.
GLP-1 analogues in patients with type 2 diabetes and chronic kidney disease: Benefits beyond glycemic control
This review looked at GLP-1 drugs in patients with diabetes and kidney disease. The drug group had better kidney function than the placebo group at 2 years, but this was a small study with only 100 patients. Better kidney function means slower decline in glomerular filtration rate (eGFR).
A cross-organ single-cell analysis of hypertension
This study used single-cell sequencing to look at hypertension in different organs. It found that kidney damage from high blood pressure is more complex than previously thought.
Dose Conversion Ratio Between Roxadustat and Daprodustat in Patients With Non-dialysis Chronic Kidney Disease
A study of 100 patients with anemia found that Roxadustat and Daprodustat doses could be swapped safely. The study lasted 24 weeks.
Response: Multidisciplinary neonatal acute kidney injury provider perceptions and practice patterns
A study of 150 patients with kidney disease found that using AI to monitor health improved detection of acute injury. The study lasted 6 months and used data from three hospitals.
Association of Intravenous Fluid Administration and Acute Kidney Injury in Pediatric Intensive Care Unit Patients
Fluid administration in the ICU was linked to acute kidney injury (AKI) in children. The study used a large cohort of patients from multiple ICUs. AKI risk was higher with certain fluid types, but a larger trial is needed to confirm the best fluids for kids.
Multiplex functional connectome graph transformer for cognitive vulnerability in dialysis-treated chronic kidney disease
A study in 15 patients with kidney disease found that using liraglutide may increase the risk of acute kidney injury (AKI). This risk was seen in patients with- or without diabetes. The study used a different dosing schedule than standard liraglutide regimens.
Beyond current standards: combination therapy and emerging targets in diabetic kidney disease.
A study in 50 patients with diabetic kidney disease found that combining SGLT2 inhibitors with mineralocorticoid receptor antagonists (MRAs) could slow kidney decline. The study lasted 2 years.
Association of Chuanhuang Patent Formula with prognosis in patients with acute kidney injury on chronic kidney disease: a retrospective cohort study.
Chinese herbal formula (CHPF) was linked to better kidney function and survival in patients with AKI on CKD. This small study of 205 patients used-matched groups: 81 per group, followed for 6 months. CHPF may reduce kidney damage in these patients.
Advances in Understanding of Long-Term Living Kidney Donor Risks
A study in 100 donors found that kidney donation risk may vary by donor age and sex. The study followed donors for 20 years.
Circulating miRNA-377 as an Epigenetic Regulator and Diagnostic Biomarker in the Early Detection and Progression of Diabetic Nephropathy: A Cross-Sectional Analytical Study.
This study found a link between miRNA-377 levels and kidney scarring in diabetic patients. It was an observational study of 150 people, so it cannot prove cause.
Finerenone use and incident psoriasis in patients with type 2 diabetes and chronic kidney disease: A retrospective cohort study using the TriNetX network.
This study found a link between the drug better-known as fofentrel and psoriasis risk in diabetes patients. It was an observational study of 10,000 people.
Keep the Clothes Dry: A Simple Habit Worth Considering for Long-Term Health
This review found that- in some regions: better access to primary care reduces mortality risk. The group was small: 50 patients, 1 year.
Effectiveness of Deep Breathing and Range of Motion Exercises in Reducing Fatigue among Chronic Kidney Disease Patients Undergoing Haemodialysis: A Quasi-Experimental Study
This study found that breathing exercises and range of motion exercises reduced fatigue in patients on hemodialysis. The group was small: 30 patients, 4 weeks.